GH Research PLCNASDAQ:GHRS
- LAST PRICE6.2400
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots5.8900/ 1
- Ask / Lots6.5500/ 1
- Open / Previous Close0.0000 / 6.2400
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | GHRS |
|---|---|---|
| 09:32 ET | 356 | 6.4 |
| 09:39 ET | 300 | 6.49 |
| 09:44 ET | 250 | 6.535 |
| 09:53 ET | 200 | 6.6152 |
| 09:55 ET | 250 | 6.42 |
| 10:00 ET | 137 | 6.58 |
| 10:04 ET | 100 | 6.4 |
| 10:06 ET | 200 | 6.4 |
| 10:08 ET | 166 | 6.4 |
| 10:11 ET | 100 | 6.395 |
| 10:20 ET | 100 | 6.3975 |
| 10:24 ET | 600 | 6.49 |
| 10:26 ET | 2000 | 6.34 |
| 10:27 ET | 200 | 6.34 |
| 10:31 ET | 200 | 6.3 |
| 10:40 ET | 10034 | 6.3 |
| 10:45 ET | 100 | 6.3 |
| 10:54 ET | 100 | 6.33 |
| 11:02 ET | 100 | 6.35 |
| 11:07 ET | 200 | 6.36 |
| 11:20 ET | 1000 | 6.5154 |
| 11:36 ET | 400 | 6.33 |
| 11:52 ET | 100 | 6.36 |
| 11:54 ET | 2400 | 6.43 |
| 11:56 ET | 2200 | 6.405 |
| 11:59 ET | 3700 | 6.33 |
| 12:10 ET | 100 | 6.3 |
| 12:12 ET | 400 | 6.465 |
| 12:30 ET | 300 | 6.35 |
| 12:37 ET | 200 | 6.3 |
| 01:02 ET | 119 | 6.44 |
| 01:15 ET | 1840 | 6.435 |
| 01:18 ET | 200 | 6.32 |
| 01:20 ET | 314 | 6.32 |
| 01:22 ET | 1675 | 6.47 |
| 01:24 ET | 400 | 6.3 |
| 01:36 ET | 807 | 6.3 |
| 01:38 ET | 1000 | 6.29 |
| 01:40 ET | 1562 | 6.28 |
| 01:42 ET | 2429 | 6.25 |
| 01:44 ET | 400 | 6.255 |
| 01:45 ET | 100 | 6.31 |
| 01:47 ET | 2711 | 6.23 |
| 01:49 ET | 1200 | 6.29 |
| 01:51 ET | 100 | 6.18 |
| 01:58 ET | 226 | 6.29 |
| 02:00 ET | 1367 | 6.25 |
| 02:02 ET | 1262 | 6.25 |
| 02:03 ET | 300 | 6.25 |
| 02:14 ET | 1200 | 6.25 |
| 02:16 ET | 100 | 6.29 |
| 02:18 ET | 1275 | 6.2 |
| 02:25 ET | 100 | 6.21 |
| 02:36 ET | 300 | 6.29 |
| 02:50 ET | 100 | 6.3 |
| 03:15 ET | 100 | 6.29 |
| 03:37 ET | 300 | 6.255 |
| 03:42 ET | 100 | 6.28 |
| 03:51 ET | 200 | 6.3 |
| 03:55 ET | 100 | 6.29 |
| 03:57 ET | 300 | 6.3 |
| 04:00 ET | 1169 | 6.24 |
Nov 14, 2023
DJ GH Research Is Maintained at Buy by HC Wainwright & Co., from 11:23AM ET on Tuesday Nov 14, 2023 by Dow Jones
11:23AM ET on Tuesday Nov 14, 2023 by Dow Jones
Nov 9, 2023
Press Release: GH Research Reports Third Quarter Financial Results and Provides Business Updates, from 4:45PM ET on Thursday Nov 09, 2023 by Dow Jones
4:45PM ET on Thursday Nov 09, 2023 by Dow JonesGH Research Reports Third Quarter Financial Results and Provides Business Updates, from 4:45PM ET on Thursday Nov 09, 2023 by Dow Jones
4:45PM ET on Thursday Nov 09, 2023 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
GH Research PLC | 324.6M | -7.9x | --- |
Immunome Inc | 341.0M | -4.4x | --- |
Kalvista Pharmaceuticals Inc | 305.8M | -2.8x | --- |
IGM Biosciences Inc | 343.9M | -1.2x | --- |
AC Immune SA | 280.1M | -3.6x | --- |
Taysha Gene Therapies Inc | 340.3M | -0.7x | --- |
Company Information
GH Research PLC is a clinical-stage biopharmaceutical company. The Company is engaged in offering treatment for psychiatric and neurological disorders. The Company's pipeline includes GH001, GH002 and GH003. The Company focuses on developing its 5- Methoxy-N, N-Dimethyltryptamine, (5-MeO-DMT), therapies for the treatment of patients with Treatment Resistant Depression (TRD). Its product candidate, GH001, is formulated for 5-MeO-DMT administration via an inhalation approach. With GH001, it has completed two Phase 1 healthy volunteer clinical trials and a Phase 1/2 clinical trial in patients with treatment-resistant depression (TRD). GH002 is its 5-MeO-DMT product candidate formulated for administration via an injectable approach. GH002 has completed pre-clinical development to support early clinical trials. GH003 is its 5-MeO-DMT product candidate formulated for administration via an intranasal administration approach.
Contact Information
- Headquarters
- Joshua Dawson House, Dawson StreetDublin, Ireland D02 RY95
- Phone
- ---
- Fax
- ---
Executives
- Non-Executive Chairman of the Board
- Florian Schonharting
- Chief Executive Officer
- Theis Terwey
- Non-Executive Independent Vice Chairman of the Board
- Michael Forer
- Vice President - Finance
- Julie Ryan
- Managing Director, Ireland
- Magnus Halle
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $324.6M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 52.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.79 |
Book Value | $4.80 |
P/E Ratio | -7.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
